特发性炎性肌病的心血管风险评估:多中心国际研究
这项多中心国际回顾性研究评估了336例特发性炎性肌病患者的心血管风险评估现状,发现超过三分之一患者按QRISK3为中等高风险,但仅34%该组患者按NICE指南接受他汀治疗,且多数中心未常规评估心血管风险。
要点
- 超过三分之一特发性炎性肌病患者按QRISK3为中等高风险。
- 仅34%中等高风险患者按NICE指南接受他汀一级预防。
- 免疫介导坏死性肌病、活动性激素使用和血脂异常与中等高风险评分相关。
核心结论
- 超过三分之一特发性炎性肌病患者10年心血管事件风险为中等高风险,且多数中心未常规评估心血管风险。
- 激素使用和血脂异常是可改变的风险因素,且为风险的显著预测因素。
- 当前指南推荐的常规心血管风险评估和他汀一级预防在中等高风险组中依从性不足。
研究设计与样本
- 多中心国际回顾性病历审查,纳入印度、香港、巴西、意大利、澳大利亚和英国中心2020至2023年就诊的特发性炎性肌病患者。
- 使用WHO心血管风险图表和QRISK3评分评估心血管风险,按10年风险分为高风险(>20%)、中等风险(10-20%)和低风险(<10%)。
- 评估对BSR和NICE指南的依从性。
主要发现
- 共纳入336例患者,除一个中心外所有中心未常规评估心血管风险。
- 超过三分之一患者按QRISK3为中等高风险,但该组仅34%按NICE指南处方他汀。
- 免疫介导坏死性肌病与中等高风险评分强相关(OR=4.64;95%CI=1.88-11.45,p<0.001)。
- 活动性激素使用(OR=1.76;95%CI=1.06-2.92,p=0.03)和血脂异常(OR=1.22;95%CI=1.03-1.45,p=0.02)与中等高风险评分相关。
- WHO与QRISK3评分之间一致性为中等水平。
关键数值与推荐
- BSR 2022指南推荐特发性炎性肌病患者应定期进行心血管风险评估。
- NICE指南推荐对10年心血管疾病风险估计≥10%的患者提供他汀治疗用于心血管疾病一级预防。
- 按QRISK3,10年心血管事件风险>20%为高风险,10-20%为中等风险,<10%为低风险。
临床怎么用
- 对特发性炎性肌病患者应常规进行心血管风险评估,尤其关注免疫介导坏死性肌病、活动性激素使用和血脂异常患者。
- 对10年心血管风险≥10%的中等高风险患者,应按NICE指南考虑他汀一级预防。
- QRISK3纳入激素使用等特发性炎性肌病相关风险因素,可能较WHO图表更适用。
局限性
- 本研究为回顾性病历审查,依赖医疗记录数据的完整性。
- 除一个中心外所有中心未常规评估心血管风险,可能影响风险评分的全面性。
- WHO与QRISK3评分之间仅为中等水平一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND AIMS: Cardiovascular disease (CVD) is a leading contributor of morbidity and mortality in patients with idiopathic inflammatory myopathies (IIM). The British Society for Rheumatology (BSR) 2022 guidelines recommend that IIM patients should undergo a regular cardiovascular risk assessment; however, many tools underestimate scores in IIM due to their sole focus on traditional risk factors. Cardiovascular Risk Score (QRISK) incorporates risk factors that are more relevant in IIM, such as corticosteroid use. The National Institute for Health and Care Excellence (NICE) guidelines recommend offering statin therapy for the primary prevention of CVD in patients with an estimated 10-year CVD risk of ≥10 %. This study aimed to undertake an audit of cardiovascular risk assessment in a multinational cohort of patients with IIM, based on BSR and NICE recommendations. METHODS: A multi-centre, international retrospective chart review was conducted in IIM cohorts from centres in India, Hong Kong, Brazil, Italy, Australia, and the United Kingdom, of patients who attended clinics between 2020 and 2023. Data were collected from medical records to evaluate CVD risk using both WHO cardiovascular risk charts and QRISK3 score. Based on their risk of cardiovascular events in the next 10 years, patients were defined as high-risk (>20 %), moderate-risk (10-20 %), or low-risk (<10 %). Adherence to the BSR and NICE guidelines was evaluated. RESULTS: A total of 336 patients were included. All centres, except one, did not routinely assess CVD risk. More than a third of patients were deemed moderate-high risk for CVD as per QRISK3, although only 34 % in this group were prescribed a statin as per NICE guidelines. Disease subtype immune-mediated necrotizing myopathy was strongly associated with moderate-high risk scores (OR = 4.64; 95 %CI = 1.88-11.45, p < 0.001), as was active steroid use [OR = 1.76 (95 % CI = 1.06-2.92), p = 0.03] and dyslipidaemia [OR = 1.22 (95 % CI = 1.03-1.45), p = 0.02]. There was a moderate level of agreement between WHO and QRISK3 scores. CONCLUSION: Over a third of patients with IIM are at moderate-high-risk of cardiovascular events in 10 years. Steroid use and dyslipidaemia were modifiable risk factors that were statistically significant predictors of risk. Despite this, there is a lack of adherence to current guidelines advising regular CVD risk assessment and use of statins for primary prevention in this moderate-high risk group.
引用
- Chin A, Rahulan LM, Lalwani D, et al. Cardiovascular risk assessment in idiopathic inflammatory myopathies: a multicentre international study by the myositis audit and research collaborative group. Semin Arthritis Rheum. 2025. PMID: 41468780. doi:10.1016/j.semarthrit.2025.152898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。